搜尋
Zymeworks Inc
ZYME添加自選
25.720USD
-0.420-1.61%
收盤 07/01, 16:00（美東）報價延遲15分鐘
1.93B總市值
虧損本益比TTM
關鍵數據
26.140今開
26.385最高
558.63K成交量
虧損本益比TTM
25.65本益比動
--股利TTM
0.74%換手率
26.140昨收
25.300最低
9.77M成交額
虧損本益比靜
7.20市淨率
0.00%股息率 TTM
-22.72%ROA
29.75052週最高
0.70量比
-122.69M淨利潤
75.19M總股本
-1.3662每股盈餘TTM
1.16Beta
-42.02%ROE
11.02052週最低
4.15%振幅
100.00%毛利率
1.93B總市值
3.26回報/風險
2.58%風險率
TradingKey Zymeworks Inc股票評分
單位: USD 更新時間: 2026-07-01操作建議
Zymeworks Inc當前公司基本面數據相對健康，增長潛力較大。當前估值合理，在生物技術與醫療研究行業排名40/387位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為39.08。中期看，股價處於平穩狀態。近一個月，市場表現較強，技術面評分較高，但較強的走勢未獲得基本面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Zymeworks Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
看好
Zymeworks Inc亮點
亮點風險
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
分析師目標
基於
12
分析師
買入
評級
39.083
目標均價
+49.52%
漲幅空間
Zymeworks Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Zymeworks Inc簡介
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
公司代碼ZYME
公司Zymeworks Inc
CEOGalbraith (Kenneth H)
網址https://www.zymeworks.com/
相關品種
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%熱門品種
52365.700
+111.400 (+0.21%)
29940.100
+140.800 (+0.47%)
7499.300
+23.800 (+0.32%)
14979.000
-376.000 (-2.45%)
69709.000
+224.000 (+0.32%)
6297.000
+21.600 (+0.34%)
67.714
-0.254 (-0.37%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4058.420
+27.650 (+0.69%)
常見問題
Zymeworks Inc(ZYME)的當前股價是多少？
Zymeworks Inc(ZYME)的當前股價是 25.72。
Zymeworks Inc 的股票代碼是什麼？
Zymeworks Inc的股票代碼是ZYME。
Zymeworks Inc股票的52週最高點是多少？
Zymeworks Inc股票的52週最高點是29.75。
Zymeworks Inc股票的52週最低點是多少？
Zymeworks Inc股票的52週最低點是11.02。
Zymeworks Inc的市值是多少？
Zymeworks Inc的市值是1.93B。
現在Zymeworks Inc(ZYME)的股票是買入、持有還是賣出？
根據分析師評級，Zymeworks Inc(ZYME)的總體評級為買入，目標價格為39.08。
Zymeworks Inc(ZYME)股票的每股收益（EPS TTM）是多少
Zymeworks Inc(ZYME)股票的每股收益（EPS TTM）是-1.08。